PT 141 (Bremelanotide) (10mg)

PT 141, or as commonly also referred to as bremelanotide, is a peptide that activates the Melanocortin 4 receptor (MC-4R) in the central nervous system in the body, causing increased sexual arousal [1, 2]. Studies in mice have also demonstrated when binding to MC-4R, sexual arousal is increased where there is increased sexual activity in both males and females [3, 4].

PT 141 (Bremelanotide) effect on various conditions:

Hemorrhagic Shock and Blood Flow Improvement

PT 141 is being researched at the present time for the treatment of hemorrhagic shock. By binding to MC-1R and MC-4R receptors, PT 141 seems to improve blood supply to tissues and assists in preventing damage in cases where blood flow is reduced and showed no side effects [2].

Treatment of Sexual Disorders

Bremelanotide may be a treatment option for sexual disorders that do not result from problems related to blood flow to the genitalia and its region. Scientists are currently studying PT 141 and its link to sexual and erectile dysfunction (SD, ED). In males suffering from ED, studies have demonstrated that PT 141 is effective in producing erections even in those who did not respond to other commonly used erectile dysfunction medications [5].

Anti-Inflammation and Anti-Fungal

In an animal study conducted not too recently, MC-1R demonstrated its ability to fight fungal infections while at the same time mitigating inflammation processes. Despite the fact that further studies are needed, MC-1R seems like a potential candidate for the treatment of fungal infections. This potential finding could offer patients with autoimmune conditions a new therapeutic avenue in the upcoming future [6].

Prevention and Treatment of Cancer

Variants of MC-1R have been linked with a potentially higher risk of basal cell and squamous cell carcinoma. MC-1R fuels the DNA repair pathways and may hold a role in the mitigation and treatment of these types of common skin cancers [7, 8].

Metabolic System and Weight Loss

PT 141, which is established above to stimulate the MC-4R, has been found to promote feelings of fullness and reduce calorie intake. A study conducted on animals suggests that PT 141 holds the potential to increase energy expenditure and improve the body’s metabolism rate at the same time. Activation of the MC-4R may increase further the body’s ability to burn calories, even when rested[9].

Weight Loss possibilities

A fairly recent study have supported the weight loss results linked with PT 141 administration. Subjects given PT 141 experienced twice as much higher weight loss rate compared to the placebo control group. The frequency of PT 141 administration (twice per day versus once per day) also influenced the amount of weight being lost [10].

Abuse Warning

SARMs should only be used under the direct supervision and direction of a trained and licensed medical doctor or a designated research authority. Sarmful strongly discourages the use of SARMs for performance enhancement in fields of various sports such as bodybuilding and achievement sports, etc.

S4 is an investigational compound still undergoing research and NOT yet FDA approved, nor it is a dietary supplement. Sarmful is solely a research chemical supplier specializing in sourcing and quality control. We are not medical doctors. Sarmful discourages strongly against “bro science” and peer consensus when making decisions about human health.

We do not encourage or condone consumer use of SARMs products, they are for research purposes only.

References and further read

1. Sandrock M, Schulz A, Merkwitz C, Schöneberg T, Spanel-Borowski K, Ricken A. Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice. Reprod Biol Endocrinol. 2009 Mar 24;7:24. doi: 10.1186/1477-7827-7-24. PMID: 19309531; PMCID: PMC2667525.

2. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135-42. doi: 10.1038/sj.ijir.3901200. PMID: 14999221.

3. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003;118(3):755-62. doi: 10.1016/s0306-4522(02)00866-7. PMID: 12710982.

4. Rössler AS, Pfaus JG, Kia HK, Bernabé J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006 Nov;85(3):514-21. doi: 10.1016/j.pbb.2006.09.023. Epub 2006 Nov 20. PMID: 17113634.

5. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18. PMID: 18206919.

6. Ji HX, Zou YL, Duan JJ, Jia ZR, Li XJ, Wang Z, Li L, Li YW, Liu GY, Tong MQ, Li XY, Zhang GH, Dai XR, He L, Li ZY, Cao C, Yang Y. The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization. PLoS One. 2013;8(2):e56004. doi: 10.1371/journal.pone.0056004. Epub 2013 Feb 14. PMID: 23457491; PMCID: PMC3573073.

7. Feller L, Khammissa RAG, Kramer B, Altini M, Lemmer J. Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med. 2016 Feb 5;12:11. doi: 10.1186/s13005-016-0106-0. PMID: 26850723; PMCID: PMC4744388.

8. Maresca V, Flori E, Picardo M. Skin phototype: a new perspective. Pigment Cell Melanoma Res. 2015 Jul;28(4):378-89. doi: 10.1111/pcmr.12365. Epub 2015 Apr 11. PMID: 25786343.

9. McMillan TR, Forster MAM, Short LI, Rudecki AP, Cline DL, Gray SL. Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. Exp Physiol. 2021 Feb;106(2):427-437. doi: 10.1113/EP088838. Epub 2020 Dec 17. PMID: 33332767.

10. Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022 Jun;24(6):1084-1093. doi: 10.1111/dom.14672. Epub 2022 Mar 15. PMID: 35170192; PMCID: PMC9314948.